Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic Markers and Personalized Intervention in MDD
NCT02023567Unknown
- Sponsor
- Peking University
- Start
- Nov 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fluoxetine, paroxetine, sertraline, citalopram, escitalopram and 1 more in major depressive disorder (MDD) (2 arms), sponsored by Peking University. Primary endpoint: Hamilton Depression Rating Scale at 8 weeks. Status: unknown.
02
Drugs
fluoxetineparoxetinesertralinecitalopramescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02023567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023567.